In this work, we report a detailed kinetic analysis of the effects of three of these bisphosphonates on homogeneous TcHK, as well as on the enzyme in purified intact glycosomes, peroxisome-like organelles that contain most of the glycolytic pathway enzymes in this organism. We also investigated the effects of the same compounds on glucose consumption by intact and digitoninpermeabilized T. cruzi epimastigotes, and on the growth of such cells in liver-infusion tryptose medium. The bisphosphonates investigated were several orders of magnitude more active than PP i as non-competitive or mixed inhibitors of TcHK and blocked the use of glucose by the epimastigotes, inducing a metabolic shift toward the use of amino acids as carbon and energy sources. Furthermore, there was a significant correlation between the IC 50 values for TcHK inhibition and those for epimastigote growth inhibition for the 12 most potent compounds of this series. Finally, these bisphosphonates did not affect the sterol composition of the treated cells, indicating that they do not act as inhibitors of farnesyl diphosphate synthase. Taken together, our results suggest that these novel bisphosphonates act primarily as specific inhibitors of TcHK and may represent a novel class of selective anti-T. cruzi agents.Chagas disease remains the major parasitic disease burden in Latin America, despite recent advances in the control of its vectorial and transfusional transmission (1, 2). Specific chemotherapy against its etiological agent, the kinetoplastid parasite Trypanosoma cruzi, is unsatisfactory because current drugs have very limited efficacy in the prevalent, chronic phase of the disease, and there are frequent serious side effects (3). Thus, there is an urgent need for safer and more potent drugs to treat this condition, and several rational approaches are being developed, exploiting key biochemical differences between the parasite and its mammalian hosts (3, 4). In this context, it is of note that T. cruzi, and several related kinetoplastid protozoa, have several unusual characteristics in their energy metabolism, which differentiates them from other eukaryotes. 1) Most of the glycolytic pathway is compartmentalized in peroxisome-like organelles termed glycosomes (5, 6). 2) The classic, allosteric modulators of the two key regulatory enzymes of the glycolytic pathway in mammalian, fungal, and bacterial organisms, hexokinase and phosphofructokinase, do not affect the kinetoplastid enzymes (7-9). This is associated with the absence of a Pasteur effect in these parasites, in addition to their flexibility in utilizing glucose or amino acids as carbon and energy sources (10 -12). 3) Kinetoplastid parasites contain large stores of inorganic pyrophosphate (PP i ) and other short chain polyphosphates, which are by far the most abundant high energy compounds in these cells (13-15).Although earlier work had shown that T. cruzi ATP-dependent hexokinase (TcHK) 2 was not inhibited by its main regulator in vertebrates, D-glucose 6-phosphate (7, 9, 16), more rec...